Boston Scientific Corporation (NYSE:BSX): Boosting Its Front Running Portfolio


Dallas, Texas 11/21/2013 (Financialstrend) – Boston Scientific Corporation (NYSE:BSX) is further boosting its front running portfolio of peripheral-embolization technologies. The company has now received United States FDA clearance and the CE Mark approval for Direxion-Torqueable Microcatheter.

Peripheral embolization is the technique that is mainly used by interventional-radiologists in the treatment of liver cancer, uterine-fibroids & other challenging conditions. This involves deliberately-blocking a blood vessel and preventing blood flow to a particular area of the body. This has been proved to be effective in shrinking a tumor / even block an aneurysm.

Professor of Radiology & the director of Interventional-Oncology at Northwestern Memorial Hospital, Riad Salem, M.D., MBA said that the Direxion Microcatheter’s exceptional handling-characteristics are intended to allow physicians to very efficiently access hose difficult-to-navigate vessels in many types of peripheral-embolization procedures

Wednesday’s trading

In Wednesday’s trading session, Boston Scientific Corporation (NYSE:BSX) rose by 0.09%. The opening price of the shares was $12.15, which was the intraday high headed to close at $11.97. Around 9.46M shares were exchanged on Wednesday while the average-volume of 13.74 million shares were traded over a 30 day period. The 52-week low of Boston Scientific Corporation (NYSE:BSX) shares is $5.18 while the 52-week high is $12.48. The company has a market capitalization of $15.98 billion.

About the company

Boston Scientific Corporation (NYSE:BSX) is a company that develops, manufactures and markets medical devices that are utilized in a variety of interventional-medical specialties. In the year that ended 31st December 2011, Boston Scientific Corporation (NYSE:BSX)’s products were up for sale via 7 core businesses: one- Interventional two- Cardiology, three-CRM, four-Endoscopy, five-Peripheral Interventions, six- Urology/Women’s Health, Neuromodulation, and seven- Electrophysiology. In 20111 January, Boston Scientific Corporation (NYSE:BSX) completed acquiring Intelect Medical, Inc. In 2012 June, it acquired Cameron Health, Inc- based in San Clemente, California. From this association, the company added to the existing product portfolio subcutaneous implantable-cardioverter defibrillator.